Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7508737 | 0.84 | HTR1A (0.35) | HTR1AKDM4EMDM2POLBTDP1 | |
| SCHEMBL2650435 | 0.78 | KDM4E (0.50) | HTR1AKDM4EMDM2LMNA | |
| SCHEMBL2649295 | 0.72 | KDM4E (0.46) | HTR1AKDM4EMDM2LMNA | |
| SCHEMBL7509118 | 0.70 | — | — | |
| SCHEMBL4612540 | 0.69 | HTR1A (0.62) | HTR1AKDM4ELMNAPOLBTDP1 | |
| SCHEMBL139066 | 0.68 | — | — | |
| SCHEMBL6244448 | 0.68 | — | — | |
| SCHEMBL5501 | 0.67 | ALDH1A1 (0.53) | KDM4EMDM2LMNAPOLB | |
| SCHEMBL5858924 | 0.67 | ALDH1A1 (0.32) | — | |
| SCHEMBL9307769 | 0.66 | LMNA (0.57) | LMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030166638-A1 | Benzimidazole's used as aminobutyric acid receptor modulators, for prophylaxis of nervous system disorders such as anxiety, sleep disorders, epilepsia or convulsions | NEUROSEARCH A/S | 2003-09-04 | — | — | US | claimed |
| US-6503925-B1 | Treating anxiety, anesthesia, and epilepsy | NEUROSEARCH A/S (DK) | 2003-01-07 | — | — | US | claimed |
| US-6218547-B1 | 1-phenyl-benzimidazole compounds and their use as GABA-a receptor modulators | NEUROSEARCH A/S (DK) | 2001-04-17 | — | — | US | claimed |
| EP-0934281-B1 | 1-PHENYL-BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS BAGA- A? RECEPTOR MODULATORS | NEUROSEARCH AS (DK) | 2010-01-06 | — | — | EP | disclosed |
| US-6710044-B2 | Technical field | NEUROSEARCH A/S (DK) | 2004-03-23 | — | — | US | disclosed |
| US-20030166638-A1 | Benzimidazole's used as aminobutyric acid receptor modulators, for prophylaxis of nervous system disorders such as anxiety, sleep disorders, epilepsia or convulsions | NEUROSEARCH A/S | 2003-09-04 | — | — | US | disclosed |
| US-6503925-B1 | Treating anxiety, anesthesia, and epilepsy | NEUROSEARCH A/S (DK) | 2003-01-07 | — | — | US | disclosed |
| US-6218547-B1 | 1-phenyl-benzimidazole compounds and their use as GABA-a receptor modulators | NEUROSEARCH A/S (DK) | 2001-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166638-A1 | Benzimidazole's used as aminobutyric acid receptor modulators, for prophylaxis of nervous system disorders such as anxiety, sleep disorders, epilepsia or convulsions | GABRA1, GABRA2, GABRA4 | HTR1A 123/4885KDM4E 1061/4885MDM2 4620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.